United Therapeutics Looks Promising with Strong Momentum $UTHR

By |December 29th, 2017|Monthly Investment Ideas|

United Therapeutics Corporation ($UTHR) recently entered into a settlement which will allow the company to pay $210 million to resolve US claim against it pertaining the use of a charity to illegally cover Medicare patients’ claims. It has been held that the company paid such expenses to artificially manage price [...]

Premarket Biotech Digest – $AGIO submits NDA, $ABBV receives favorable ruling, $MNK seals acquisition deal

By |December 26th, 2017|Digest|

Insys Therapeutics ($INSY) reacted positively to the news that the FDA has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, an inherited disorder characterized by weak muscle tone, feeding difficulties, delayed development and poor growth. [...]

GW Pharmaceuticals looks strong as it seeks FDA approval for new drug $GWPH

By |December 22nd, 2017|Monthly Investment Ideas|

GW Pharmaceuticals PLC ($GWPH) recently reported its fourth quarter and full year financial results. The company’s revenue for the twelve months ended 30 September 2017 of £8.2 million ($11.0 million) compared to £10.3 million for the twelve months ended 30 September 2016. Its loss for the twelve months ended 30 [...]

Premarket Biotech Digest – $RXII reports positive results, $NVS gets breakthrough therapy designation, $IIN reports collaboration

By |December 19th, 2017|Digest|

BaiGene ($BGNE) stock reacted positively to the news that the company disclosed that the first patient has been dosed in a pivotal Phase 2 clinical trial evaluating PARP inhibitor pamiparib. The drug was used in Chinese patients with advanced BRCA mutation-positive ovarian cancer who [...]

Galapagos looks strong with robust product pipeline development $GLPG

By |December 15th, 2017|Monthly Investment Ideas|

Galapagos NV ($GLPG) recently announced starting its Phase 1 study of its drug candidate GLPG3221 to evaluate its safety, tolerability and pharmacokinetics in healthy volunteers. GLPG3221 is the second C2 corrector, chemically distinct from the first C2 corrector. The company is developing the drug candidate in collaboration with AbbVie. The [...]

Premarket Biotech Digest – $XENT gets FDA approval, $AGN announces acquisition, $IONS licenses product

By |December 12th, 2017|Digest|

Shineco Inc ($TYHT) stock jumped as the company announced its share exchange and acquisition agreement with strategic partner Western Xinjiang Tiansheng Agricultural Development Co., Ltd. The terms and conditions of the agreement provide for Xinjiang Shineco Taihe Agricultural Technology Ltd. to receive a 51% [...]

Decline in price makes BioMarin an attractive Investment Opportunity $BMRN

By |December 8th, 2017|Monthly Investment Ideas|

BioMarin Pharmaceuticals Inc. ($BMRN) reported its second quarter results. The company announced its revenue for the period at $317.4 million, up 6 percent on year over year basis. The tepid growth is mainly on account of disappointing performance shown by its top performing drug Vimizim. The revenue from the drug [...]

Premarket Biotech Digest – $NBRV completes enrolment, $LLY receives FDA approval, $FBIO inks new deal

By |December 5th, 2017|Digest|

NeoGenomics Inc. ($NEO) reported inking a new deal with Thermo Fisher Scientific. The deal allows the company to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. NeoGenomics offers the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer (NSCLC). It [...]

Alkermes Set to Benefit from New Product Development $ALKS

By |December 1st, 2017|Monthly Investment Ideas|

Alkermes Plc ($ALKS) has a couple of positive developments coming its way. The company recently reported positive results from a phase 4 clinical study of ARISTADA® extended-release injectable suspension for the treatment of schizophrenia. The data showed that a flexible dose regimen of the drug at 441 mg, 662 mg [...]

Premarket Biotech Digest – $PLX reports +ve results, $CRBP granted new patent, $ESRX inks new deal

By |November 28th, 2017|Digest|

Benitec Biopharma Ltd. ($BNTC) provided update about its Investigational New Drug application in the US for its gene therapy BB-301 for the treatment of oculopharyngeal muscular dystrophy (OPMD). The company plans to file the IND application in the fourth quarter of 2018. Benitec plans [...]

Acorda Therapeutics stock suffers as the company suspends Parkinson’s drug development $ACOR

By |November 24th, 2017|Monthly Investment Ideas|

Acorda Therapeutics Inc. ($ACOR) continues to battle with troubles as its stock suffers another setback in the markets. The company announced the discontinuation of its Parkinson’s disease drug. The decision was taken after five deaths were reported in key studies testing the treatment. Last week, Acorda reported these deaths in [...]

Premarket Biotech Digest – $DCPH reports positive data, $LIVN inks new deal, $JNJ receives EC nod

By |November 21st, 2017|Digest|

Deciphera Pharmaceuticals Inc. ($DCPH) reported positive interim data from a Phase 1 clinical trial evaluating its lead candidate DCC-2618 in patients with malignant gliomas. Off four evaluable patients with glioblastoma multiforme (GBM), one experienced a partial response with 94% tumor reduction at week 84. [...]

Jazz Pharmaceuticals looks promising with Q3 results $JAZZ

By |November 17th, 2017|Monthly Investment Ideas|

Jazz Pharmaceuticals ($JAZZ) is a pharma company with a highly diversified product portfolio. It has drug candidates for a wide range of conditions. However, the company is grappling with a number of issues as well. On the positive side, the company recently announced receiving the FDA approval for its drug [...]

Premarket Biotech Digest – $TCON reports +ve data, $IONS starts new trial, $GSK received EC approval

By |November 14th, 2017|Digest|

Tracon Pharmaceuticals ($TCON) reported positive results from a  Phase 1 clinical trial assessing TRC102 (methoxyamine) and the chemo agent Fludara (fludarabine) in patients with advanced blood cancers. The program had enrolled 20 patients with a range of blood cancers. Each received one of five [...]

Bioverativ looks strong after reporting strong Q3 results $BIVV

By |November 10th, 2017|Monthly Investment Ideas|

Bioverativ Inc. ($BIVV) recently reported its third quarter financial results. The company reported 27.2 percent Year over Year increase in its quarterly revenue to $291.6 million. However, its GAAP net income dropped 15.7 percent and its GAAP EPS dipped 16 percent to $0.63.  Bioverativ showed increase in its Non-GAAP metrics [...]

Premarket Biotech Digest – $KERX gets FDA nod, $CBMG opens China facility, $MDT gets CE mark

By |November 7th, 2017|Digest|

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the FDA has approved its Auryxia for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis. Auryxia is the only oral treatment option available in the market which is developed and approved [...]

AbbVie Reports Strong Quarterly Results, Fueling Stock Growth $ABBV

By |November 3rd, 2017|Monthly Investment Ideas|

AbbVie Inc. ($ABBV) recently reported its financial results for the third quarter. The company’s adjusted EPS for the quarter stood at $1.41 while its net revenue was reported at $6.995 billion. AbbVie also reported 15.8 percent increase in its Humira revenue. It reported solid growth for its Imbruvica product with [...]

Premarket Biotech Digest – $MRK withdraws marketing application, $DEPO settles dispute, $BHVN announces new collaboration

By |October 31st, 2017|Digest|

Kura Oncology Inc. ($KURA) announced encouraging preclinical data on leukemia candidate KO-539, a selective inhibitor of the menin-MLL protein-protein interaction. The drug candidate showed significant activity in new genetically defined subsets of acute myeloid leukemia, beyond the original target of MLL-rearranged leukemias. The company [...]

Amgen stock set to grow as the company reports strong Q3 results, revises guidance $AMGN

By |October 27th, 2017|Monthly Investment Ideas|

Amgen Inc. ($AMGN) reported upbeat third quarter financial results. The company announced 3 percent increase in its GAAP earnings per share to $2.76, while its non GAAP EPS increased 8 percent to $3.27 driven by higher operating margins. However, the decline in the company’s revenue continued as it reported 1 [...]

Premarket Biotech Digest – $VICL inks new deal, $VIVO receives FDA warning letter, $ALXN gets approval

By |October 24th, 2017|Digest|

Intercept Pharmaceuticals ($ICPT) stock shot up as the company announced positive results for its from a Phase 2 clinical trial, AESOP, evaluating obeticholic acid (OCA) for the treatment of primary sclerosing cholangitis. The company reported that patients receiving 5 mg OCA per day (with [...]

s2Member®